BioSpace News Archive

BioCareSD, a specialty distributor of life-saving therapies, today announced the addition of VIBATIV® and ULTOMIRIS® to its already extensive portfolio of life-saving therapies.

Phanes Therapeutics, Inc. (Phanes) today announced a clinical supply agreement with BeiGene, Ltd. (NASDAQ: BGNE) to evaluate the safety and efficacy of Phanes’ PT199, a differentiated anti-CD73 monoclonal antibody in combination with BeiGene’s tislelizumab, an anti-PD-1 monoclonal antibody in the Phase I clinical study (NCT05431270) for the treatment of multiple advanced solid tumors.

10x Genomics, Inc., a life sciences leader focused on mastering biology to advance human health, announced the first commercial shipments of its Xenium platform for in situ analysis.

The total number of exercisable at a Shareholders’ Meeting voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company.

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabometyx® (cabozantinib) in combination with atezolizumab (Tecentriq®).

Exelixis, Inc. (Nasdaq: EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX®).

Syndax Pharmaceuticals, Inc. announced that in connection with the hiring, announced on December 5, 2022, of Steve M. Sabus as Chief Commercial Officer, Mr. Sabus received an inducement award to purchase up to 220,000 shares of common stock.

Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents per share on the $.10 par value common stock of the company.

Certara, Inc. announced that Arsenal Capital Partners, a private equity firm specializing in investing in and building transformational healthcare companies, closed its previously announced $449 million new investment in Certara.

Caeregen Therapeutics, LLC, a Michigan-based, regenerative medicine therapeutics company, today announced the U.S. Food and Drug Administration (FDA) designated Noregen™ for treatment of Familial Exudative Vitreoretinopathy (FEVR) as a drug for “rare pediatric disease*”.